Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer

Conclusions: Ki67 assessed by RT-PCR assay was weakly correlated to Ki67 by IHC. Using 5.68 as cutoff point, Ki67 by RT-PCR had shown potential as a prognostic biomarker in HR+/HER2- early breast cancer.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research